Organogenesis Holdings Inc. (ORGO) research
Organogenesis Holdings Inc.- Sector
- Biotechnology
- Last price
- $1.33
- As of
Organogenesis Holdings Inc. (ORGO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for ORGO. Method and limitations.
Share the ORGO intelligence card
See the full ORGO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ORGO on one page. Preview it with sample data, then open it live with a free account.
Preview the ORGO dossierActive signals for ORGO
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +52% to ORGO (2026Q2)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 58% of ORGO (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 98.9%, EPS $-0.71 vs $-0.357 estimate
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 62% of ORGO (2026Q1)
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 90% of ORGO (2026Q1)
FREE, NO ACCOUNT
Every signal on ORGO, as it fires
You are seeing 5 of 9 signals recorded on ORGO since 2026-05-24.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ORGO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 68621F102 · 2026Q2 | $7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 68621F102 · 2026Q2 | $2.5M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 68621F102 · 2026Q2 | $2.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 68621F102 · 2026Q2 | $28K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ORGO
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ORGO against its peers
ORGO's operating margin of 7.9% ranks in the 96th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | ORGO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 564M USD | 13.9M USD | 96 | 13 |
| Operating margin | 7.9% | -354.5% | 96 | 12 |
| Net margin | 6.6% | -171.5% | 81 | 12 |
| Return on equity | 12.3% | -49.8% | 89 | 21 |
| P / E | 8.9x | n/a | n/a | 2 |
Peers (23): PYXS, CHRS, CNTN, PEPG, MSLE, MDWD, DTIL, CMPX, NKTX, ORMP, AVXL, ALXO, ACOG, IPHA, ADAG, NGEN, CUE, NAUT, NBP, NERV, ALEC, ELDN, XGN. Left out: VRXA (no annual filing), TNXP (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ORGO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ORGO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ORGOand get the insider, 13F, options, and confluence read in one view.